CFRX - ContraFect Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
8.80
-0.01 (-0.11%)
At close: 4:00PM EST

8.73 -0.07 (-0.80%)
After hours: 4:01PM EST

Stock chart is not supported by your current browser
Previous Close8.81
Open8.32
Bid8.76 x 800
Ask9.89 x 1200
Day's Range8.25 - 8.90
52 Week Range2.69 - 13.40
Volume202,247
Avg. Volume271,847
Market Cap134.922M
Beta (5Y Monthly)0.76
PE Ratio (TTM)20.00
EPS (TTM)0.44
Earnings DateMar 11, 2020 - Mar 15, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.33
  • GlobeNewswire

    ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to exebacase for the treatment of MRSA bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients.

  • CFRX: Updated Financials Following 1:10 Reverse Split; Phase 3 DISRUPT Trial Underway…
    Zacks Small Cap Research

    CFRX: Updated Financials Following 1:10 Reverse Split; Phase 3 DISRUPT Trial Underway…

    By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Financial Update On February 4, 2020, ContraFect (NASDAQ:CFRX) announced a one-for-ten reverse stock split. We have updated this report to reflect this change. On December 17, 2019, ContraFect announced the pricing of an underwritten public offering in which the company sold 25.65 million shares (2.565 million following 1:10

  • GlobeNewswire

    ContraFect Announces One-for-Ten Reverse Stock Split

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced a one-for-ten reverse stock split of its shares of common stock. Stockholders of ContraFect approved an amendment to the Company’s Certificate of Incorporation to effect the reverse stock split at a Special Meeting of Stockholders held on January 31, 2020. The reverse stock split is intended to give ContraFect greater flexibility in considering and planning for future potential business needs and to increase the per share trading price of the Company’s common stock to satisfy the $1.00 minimum price requirement for continued listing on The Nasdaq Capital Market.

  • GlobeNewswire

    ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Jane E. Ambler, Ph.D. has been appointed as Vice President of Clinical Microbiology. Dr. Ambler will lead the the Company’s microbiology efforts in support of the pivotal Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) superiority study of exebacase in patients with Staphylococcus aureus bacteremia, including right-sided endocarditis and in advancement of the Company’s pipeline of DLAs. Dr. Ambler has over 25 years of experience in clinical laboratory microbiology and antimicrobial drug development, and she has numerous book and journal publications.

  • GlobeNewswire

    ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including Lysins and Amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has been granted two oral presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held from April 18-21, 2020, in Paris, France. The oral presentations include new data demonstrating the ability of the Company’s lead compound, exebacase, to resensitize methicillin-resistant Staph aureus (MRSA) to methicillin-derivatives in an animal model of infective endocarditis. Exebacase is currently being studied in the Pivotal Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis.

  • GlobeNewswire

    ContraFect to Present at 2020 ASM Biothreats

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research has been invited to discuss the potential role of DLAs to combat high consequence biodefense and biologic threats at 2020 American Society of Microbiology (ASM) Biothreats, being held January 28 – 30, 2020 at the Hyatt Regency Crystal City in Arlington, Virginia. Dr. Cassino will also discuss the potential role of the Company’s lead product candidate exebacase, currently being studied in a pivotal Phase 3 trial, in addressing the downstream threat of hospital-acquired MRSA bacteremia for a potential bio-threat exposure with mass casualty events.

  • CFRX: Phase 3 DISRUPT Trial Underway…
    Zacks Small Cap Research

    CFRX: Phase 3 DISRUPT Trial Underway…

    By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Phase 3 DISRUPT Trial Underway On January 10, 2020, ContraFect Corp. (NASDAQ:CFRX) announced the first patient has been dosed in the Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase in patients with Staphylococcus aureus bacteremia, including right-sided endocarditis

  • GlobeNewswire

    ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has extended early access to exebacase to individual named patients with chronic post-operative prosthetic joint infections (PJIs) under Temporary Authorizations for Use (ATUs) from the French National Agency for Medicines and Health Products Safety (ANSM) in collaboration with Dr. Tristan Ferry at the Hôpital de la Croix Rousse in Lyon, France. Based on promising clinical signals in these exebacase-treated patients, temporary authorization for use of exebacase has now been extended to patients with Staphylococcal PJI occurring early in the postoperative period, to potentially avoid significant loss of function.

  • GlobeNewswire

    ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the first patient has been dosed in the Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis.

  • GlobeNewswire

    ContraFect to Present at Biotech Showcase 2020

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Roger J. Pomerantz, MD, President, Chief Executive Officer, and Chairman of ContraFect will present an update on the recently initiated pivotal Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis, and a general corporate overview at the Biotech Showcase on Monday, January 13, 2020, at 2:30 PM PT (5:30 PM ET) in San Francisco, CA. ContraFect is a biotechnology company focused on discovering and developing differentiated biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings.

  • Barrons.com

    Pfizer Bought a Penny Biotech Stock Just Before It Doubled

    The pharma giant invested $3 million in ContraFect stock in mid-December, paying 27 cents a share. Pfizer is now the company’s top holder.

  • Were Hedge Funds Right About Dumping ContraFect Corp (CFRX)?
    Insider Monkey

    Were Hedge Funds Right About Dumping ContraFect Corp (CFRX)?

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • GlobeNewswire

    ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced the initiation of its Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis.

  • GlobeNewswire

    ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has selected its next product candidate, CF-370, an engineered lysin targeting Pseudomonas aeruginosa (P. aeruginosa). The Company will rapidly advance CF-370 into IND-enabling studies, as the first lysin with potential to address systemic human infections caused by the Gram-negative pathogen P. aeruginosa.

  • GlobeNewswire

    ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the pricing of its underwritten public offering of 25,650,000 shares of its common stock at a public offering price of $0.39 per share. The gross proceeds from the offering will be approximately $10 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ContraFect. All shares in the offering are to be sold by ContraFect.

  • GlobeNewswire

    NexImmune Appoints Sol Barer as Chairman of the Board of Directors

    GAITHERSBURG, Md., Dec. 16, 2019 -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune.

  • CFRX: Financing Raises $12 Million, including $3 Million from Pfizer…
    Zacks Small Cap Research

    CFRX: Financing Raises $12 Million, including $3 Million from Pfizer…

    By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Financial Update On December 10, 2019, ContraFect Corp. (NASDAQ:CFRX) announced pricing of a previously announced public offering in which the company sold 37.15 million shares of common stock at an offering price of $0.27 per share. Concurrently, the company sold approximately 11.1 million shares at $0.27 per share to Pfizer,

  • GlobeNewswire

    ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the pricing of its underwritten public offering of 37,150,000 shares of its common stock at a public offering price of $0.27 per share. The gross proceeds from the public offering will be approximately $10 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ContraFect. In addition, ContraFect also announced that Pfizer Inc. has agreed to purchase 11,111,111 shares of ContraFect’s common stock pursuant to a stock purchase agreement with ContraFect at the price per share in the public offering, in a separate private placement transaction that is expected to close concurrently with the public offering.

  • Benzinga

    The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares

    The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...

  • GlobeNewswire

    ContraFect Corporation Announces Proposed Public Offering of Common Stock and Concurrent Private Placement of Common Stock to Pfizer Inc.

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. ContraFect also announced that Pfizer Inc. has entered into a stock purchase agreement with ContraFect pursuant to which Pfizer has agreed to purchase up to $3 million of shares of ContraFect’s common stock, at a price per share equal to the price per share in the proposed public offering, in a separate private placement transaction that is expected to close concurrently with the public offering.

  • GlobeNewswire

    ContraFect to Present at the Piper Jaffray 31st Annual Healthcare Conference

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Roger J. Pomerantz, MD, President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019, at 12:00 PM ET in New York City. ContraFect is a biotechnology company focused on discovering and developing differentiated biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings.

  • CFRX: Phase 3 Trial for Exebacase in MRSA Patients Underway Soon…
    Zacks Small Cap Research

    CFRX: Phase 3 Trial for Exebacase in MRSA Patients Underway Soon…

    By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Phase 3 Clinical Trial to Initiate in 4Q19 On October 2, 2019, ContraFect Corp. (NASDAQ:CFRX) announced that following a successful ‘end-of-Phase 2’ meeting with the FDA the company is planning to conduct a single Phase 3 clinical trial of exebacase in patients with Staphylococcus aureus bacteremia, including

  • GlobeNewswire

    ContraFect Reports Third Quarter 2019 Financial Results and Provides Business Update

    YONKERS, N.Y., Nov. 12, 2019 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.

  • GlobeNewswire

    ContraFect to Present at the World Anti-Microbial Resistance Congress 2019

    ContraFect is a biotechnology company focused on discovering and developing differentiated biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections.

  • CFRX: Planning to Initiate Phase 3 Superiority Trial for Exebacase in 4Q19...
    Zacks Small Cap Research

    CFRX: Planning to Initiate Phase 3 Superiority Trial for Exebacase in 4Q19...

    By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Phase 3 Clinical Trial to Initiate in 4Q19 On October 2, 2019, ContraFect Corp. (NASDAQ:CFRX) announced that following a successful ‘end-of-Phase 2’ meeting with the FDA the company is planning to conduct a single Phase 3 clinical trial of exebacase in patients with Staphylococcus aureus bacteremia, including